Compare AstraZeneca plc (AZN) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Under Armour Inc Class A — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Under Armour Inc Class A trades at $5.29 (market cap $2.26B). The key difference: AstraZeneca plc is far larger — about 109.8× Under Armour Inc Class A's market cap, and AstraZeneca plc pays a 2.01% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| AZN | UAA | |
|---|---|---|
Market Cap | $248.14B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $8.14 |
52-Week Low | $147.06 | $4.17 |
Enterprise Value | $275.41B | $3.24B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Under Armour (UAA) is trading at $5.245, down 10.49% today, reflecting ongoing challenges with revenue declines and negative profitability. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a net loss of -$201.27M in 2025 and negative cash flow trends. Recent Q1 2027 earnings beat expectations but revealed weaker revenue and cautious guidance, with management maintaining profitability outlook despite sales headwinds.
The outlook remains challenging with declining revenues and negative margins, though current valuation metrics appear reasonable. Key risks include weak North American demand and competitive pressures, while potential catalysts include new product collaborations and cost management. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
